ESR1 and breast carcinoma: Researchers in some other studies have proposed the ER-independent therapeutic potential of tamoxifen, including in antiangiogenesis [29], induction of mitochondrial dysfunction [30] and activation of Hsp90 [31], but none of these studies were conducted in breast cancer cells.